Literature DB >> 8825891

Neurodevelopmental profile of infants and toddlers with oculo-auriculo-vertebral spectrum and the correlation of prognosis with physical findings.

M S Cohen1, C A Samango-Sprouse, H J Stern, D A Custer, D R Vaught, H M Saal, C J Tifft, K N Rosenbaum.   

Abstract

We studied the neurodevelopmental profile of infants and toddlers with oculo-auriculo-vertebral spectrum (OAV) and determined if certain physical manifestations were indicative of a poor neurodevelopmental prognosis. Twenty-four patients with OAV, aged birth to 57 months, were seen in the Department of Medical Genetics at Children's National Medical Center for multidisciplinary evaluations, including neurodevelopmental assessments. Fifty-eight percent of these children scored more than 2 standard deviations below the mean in at least one domain of development. There was no difference in developmental outcome of boys versus girls, children affected unilaterally on the right side versus left side, and those with severe clinical manifestations versus those with a milder form. Children with OAV and abnormal muscle tone had lower cognitive, gross motor, and expressive language scores (P = 0.05, P = 0.002, and P = 0.02, respectively). Those affected bilaterally had lower cognitive, fine motor, receptive language, and expressive language scores (P = 0.06, P = 0.03, P = 0.03, P = 0.02, respectively). Children with cervical spine abnormalities had lower cognitive, fine motor, and expressive language scores (P = 0.02, P = 0.04, and P = 0.04, respectively). We conclude that infants and toddlers with OAV are at increased risk for neurodevelopmental delay, especially those with abnormal muscle tone, bilateral involvement, and cervical vertebral anomalies. The complexity of the neurodevelopmental problems is strongly suggestive of central nervous system disturbances. Patients with OAV need comprehensive evaluation by a multidisciplinary team to define potential neurodevelopmental delays, allow for early intervention services, and promote an optimal developmental outcome.

Entities:  

Mesh:

Year:  1995        PMID: 8825891     DOI: 10.1002/ajmg.1320600610

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  6 in total

1.  Methods and Challenges in a Cohort Study of Infants and Toddlers With Craniofacial Microsomia: The Clock Study.

Authors:  Daniela V Luquetti; Matthew L Speltz; Erin R Wallace; Babette Siebold; Brent R Collett; Amelia F Drake; Alexis L Johns; Kathleen A Kapp-Simon; Sara L Kinter; Brian G Leroux; Leanne Magee; Susan Norton; Kathleen Sie; Carrie L Heike
Journal:  Cleft Palate Craniofac J       Date:  2019-01-08

2.  Intelligence and Academic Achievement of Adolescents with Craniofacial Microsomia.

Authors:  Matthew L Speltz; Erin R Wallace; Brent R Collett; Carrie L Heike; Daniela V Luquetti; Martha M Werler
Journal:  Plast Reconstr Surg       Date:  2017-09       Impact factor: 4.730

3.  Neurodevelopment of Infants with and without Craniofacial Microsomia.

Authors:  Matthew L Speltz; Kathleen A Kapp-Simon; Alexis L Johns; Erin R Wallace; Brent R Collett; Leanne Magee; Brian G Leroux; Daniela V Luquetti; Carrie L Heike
Journal:  J Pediatr       Date:  2018-04-22       Impact factor: 4.406

4.  Neurodevelopmental outcomes in children with hemifacial microsomia.

Authors:  Brent R Collett; Matthew L Speltz; Yona Keich Cloonan; Brian G Leroux; Judith P Kelly; Martha M Werler
Journal:  Arch Pediatr Adolesc Med       Date:  2011-02

5.  Speech, Language, and Communication Skills of Adolescents With Craniofacial Microsomia.

Authors:  Brent R Collett; Kathy Chapman; Erin R Wallace; Sara L Kinter; Carrie L Heike; Matthew L Speltz; Martha Werler
Journal:  Am J Speech Lang Pathol       Date:  2019-10-03       Impact factor: 2.408

6.  Evaluation of Swallow Function in Patients with Craniofacial Microsomia: A Retrospective Study.

Authors:  Lara S van de Lande; Cornelia J J M Caron; Britt I Pluijmers; Koen F M Joosten; Marloes Streppel; David J Dunaway; Maarten J Koudstaal; Bonnie L Padwa
Journal:  Dysphagia       Date:  2017-11-04       Impact factor: 3.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.